Core Viewpoint - Zenas BioPharma is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [3]. Group 2: IPO Details - The company sold over 13 million shares at a price of $17.00 each during its IPO [3]. - The IPO registration statement claimed that Zenas BioPharma could fund its operations for 24 months using existing cash and anticipated IPO proceeds [3]. Group 3: Allegations and Financial Impact - The class action lawsuit alleges that the IPO documents were materially false and misleading, particularly regarding the funding timeline [3]. - On November 12, 2024, Zenas BioPharma disclosed in its quarterly report that it could only fund operations for 12 months, contradicting the earlier statement [4]. - As of April 15, 2025, the stock price had dropped to $8.72, representing a decline of 48.7% from the IPO price [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased or acquired Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost or obligation to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The firm is reminding investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Zenas [3]. - The complaint alleges that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [5]. Group 2: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Zenas' conduct [7].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding its financial sustainability and operational funding timeline [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Buathongsri v. Zenas BioPharma, Inc., allows investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, to seek lead plaintiff status by June 16, 2025 [1][5]. - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations, stating it could sustain for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock price was $8.72, which is 48.7% lower than the IPO price of $17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares at $17.00 each during its IPO [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securities class action services for four out of the last five years [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the June 16, 2025 deadline to become a lead plaintiff in a securities class action lawsuit related to the company's September 2024 IPO [1][5]. Group 1: Legal Action Details - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 16, 2025 [3]. - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding the company's financial sustainability and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them for discussions regarding their legal rights [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to reach out to the firm [6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [2]. IPO Details - The company conducted its IPO on September 13, 2024, selling over 13 million shares at a price of $17.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false and misleading, specifically overstating the duration Zenas BioPharma could fund its operations with existing cash and expected IPO proceeds [3]. - It was later revealed that Zenas BioPharma could only fund its operations for 12 months instead of the 24 months previously stated in the IPO registration [4]. Stock Performance - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, which is 48.7% lower than the IPO price [4]. Legal Process - Investors who purchased Zenas BioPharma securities can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased or acquired Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost or obligation to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product candidate acquisition strategy to identify and develop therapies that provide superior clinical benefits to patients [3] Upcoming Events - Zenas BioPharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET [1] - A live webcast and archived replay of the presentation will be available on the company's website under the "Events and Presentations" section [2]

Core Viewpoint - A class action lawsuit has been filed against Zenas Biopharma, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Zenas Biopharma overstated the sustainability of its operations based on existing cash and expected IPO proceeds, leading to false and misleading public statements during the IPO period [2]. - Investors who purchased securities linked to the IPO on September 13, 2024, are encouraged to contact the law firm before June 16, 2025, to participate in the lawsuit [1][2]. Group 2: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [3]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].